Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)

v3.10.0.1
Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 05, 2017
USD ($)
Feb. 01, 2012
USD ($)
Dec. 31, 2005
USD ($)
Aug. 31, 2018
USD ($)
CompensationPlan
Aug. 31, 2017
USD ($)
Aug. 31, 2018
USD ($)
CompensationPlan
Deliverables
Segments
Unit
shares
Aug. 31, 2017
USD ($)
Nov. 30, 2017
USD ($)
Debt Securities, Available-for-sale [Line Items]                
Number of deliverables for revenue recognized | Deliverables           2    
Period of doubtful for accounts receivable due from client           21 years    
Contracted storage periods option two           21 years    
Contracted storage periods option one           1 year    
Contracted storage periods option three           Lifetime    
Deferred revenue recognition period           12 months    
Valuation allowance       $ 1,605,000   $ 1,605,000   $ 2,316,000
U.S. Income tax expense (benefit)       245,000 $ 437,000 3,741,000 $ 1,039,000  
Income tax expense related to the reduction of the federal tax           $ 2,985,000    
Federal tax rate           21.00%    
Foreign income tax expense       58,000 53,000 $ 80,000 89,000  
Minimum percentage probability of realized tax benefit on settlement           50.00%    
Provisions for interest or penalties related to uncertain tax positions       0 0 $ 0 0  
Uncertain tax provisions       0 0 0 0  
Impairment on long lived assets       0 0 0 0  
Goodwill       $ 2,007,976   $ 2,007,976   0
Number of employee stock based compensation plan | CompensationPlan       2   2    
Stock-based option compensation expense       $ 55,000 238,000 $ 324,000 709,000  
Stock compensation expense reversed           $ 444,000    
Stock compensation, number of shares opted to lump sum cash payment | shares           30,000    
Unrealized holding gain and loss, trading securities       37,536 4,784 $ 12,328 (60,425)  
Unrealized gain on marketable securities, net of tax       285,255 $ 34,038 405,255 $ 60,678  
Payment warranty     $ 50,000          
Increased payment warranty   $ 75,000            
Additional payment warranty   $ 10,000            
Reserves recorded under programs       $ 18,000   $ 18,000   $ 18,000
Duke University [Member]                
Debt Securities, Available-for-sale [Line Items]                
Asset purchase agrrement closing date           Jan. 31, 2020    
Accounts Receivable [Member]                
Debt Securities, Available-for-sale [Line Items]                
Period of doubtful for accounts receivable due from client           30 days    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member]                
Debt Securities, Available-for-sale [Line Items]                
Number of reportable segments | Segments           3    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]                
Debt Securities, Available-for-sale [Line Items]                
Inventory, in units | Unit           5,917    
Number of units, per month | Unit           12    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member] | Maximum [Member]                
Debt Securities, Available-for-sale [Line Items]                
Inventory, in units | Unit           144    
PrepaCyte CB [Member]                
Debt Securities, Available-for-sale [Line Items]                
Payment warranty $ 75,000              
Increased payment warranty $ 100,000